News in brief: Darolutamide listed on PBS for nmCRPC; AMA ‘secession’ move slammed; COVID-19 boosters now available for doctors

Darolutamide listed on PBS for nmCRPC Darolutamide (Nubeqa) is now PBS-listed for the treatment of men with non-metastatic castration resistant prostate cancer (nmCRPC). From 1 November the oral androgen receptor inhibitor will be subsidised for the treatment of patients with m0CRPC at risk of progression because of rising PSA levels, in combination with standard androgen ...

Already a member?

Login to keep reading.

© 2022 the limbic